Improving outcomes of severe infections by multidrug-resistant pathogens with polyclonal IgM-enriched immunoglobulins

Clinical Microbiology and Infection

Volumn 22, Issue 6, 2016, Pages 499-506

  Giamarellos Bourboulis, E J ^a   Tziolos, N ^a   Routsi, C ^a   Katsenos, C ^b   Tsangaris, I ^a   Pneumatikos, I ^c   Vlachogiannis, G ^d   Theodorou, V ^c   Prekates, A ^e   Antypa, E ^f   Koulouras, V ^g   Kapravelos, N ^h   Gogos, C ⁱ   Antoniadou, E ^f   Mandragos, K ^b   Armaganidis, A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b KAT HOSPITAL   (Greece)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^d Aristotle University and Hippokration General Hospital   (Greece)

^e TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^f G GENNIMATAS GENERAL HOSPITAL   (Greece)

^g UNIVERSITY OF IOANNINA   (Greece)

^h G PAPANICOLAOU HOSPITAL   (Greece)

ⁱ UNIVERSITY OF PATRAS   (Greece)

Author keywords

Antimicrobial resistance; bacteraemia; IgM immunoglobulin; mortality; septic shock

Indexed keywords

IMMUNOGLOBULIN M; IMMUNOLOGIC FACTOR;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CLOTTING DISORDER; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GRAM NEGATIVE BACTERIUM; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SEPTIC SHOCK; AGED; CLINICAL TRIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; GREECE; MICROBIOLOGY; MORTALITY; MULTICENTER STUDY; MULTIDRUG RESISTANCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GREECE; HUMANS; IMMUNOGLOBULIN M; IMMUNOLOGIC FACTORS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84961813355     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2016.01.021     Document Type: Article

References (19)

1. [1] Capone, A., Giannella, M., Fortini, D., Giordano, A., Meledandri, M., Ballardini, M., et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 19 (2013), E23–E30.
2. [2] Gudiol, C., Tubau, F., Catalayud, L., Garcia-Vidal, C., Cisnal, M., Sánchez-Ortega, I., et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 66 (2011), 657–663.
3. [3] Koupetori, M., Retsas, T., Antonakos, N., Vlachogiannis, G., Perdios, I., Nathanail, C., et al. Bloodstream infections and sepsis in Greece: over-time change of epidemiology and impact of de-escalation on final outcome. BMC Infect Dis, 14, 2014, 272.
4. [4] Hotchkiss, R.S., Monneret, G., Payen, D., Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 13 (2013), 260–268.
5. [5] Lu, Q., Rouby, J.J., Laterre, P.F., Eggimann, P., Dugard, A., Giamarellos-Bourboulis, E.J., et al. Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. J Antimicrob Chemother 66 (2011), 1110–1116.
6. [6] Rossmann, F.S., Kropec, A., Laverde, D., Saaverda, F.R., Wobser, D., Huebner, J., In vitro and in vivo activity of hyperimmune globulin preparations against multiresistant nosocomial pathogens. Infection 43 (2014), 169–173.
7. [7] Bulletin on sepsis. Hellenic Sepsis Study Group www.sepsis.gr.
8. [8] Calandra, T., Cohen, J., The International Sepsis Forum Consensus definitions of infections in the intensive care unit. Crit Care Med 33 (2005), 1639–1648.
9. [9] Magirakos, A.P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M.E., Giske, C.G., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18 (2012), 268–281.
10. [10] Charslon, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987), 373–383.
11. [11] Giamarellos-Bourboulis, E.J., Apostolidou, E., Lada, M., Perdios, I., Gatselis, N.K., Tsangaris, I., et al. Kinetics of circulating immunoglobulin M in sepsis: relationship with final outcome. Crit Care, 17, 2013, R247.
12. [12] Bermejo-Martin, J.F., Rodriguez-Fernandez, A., Herrán-Monge, R., Andaluz-Ojeda, D., Muriel-Bombín, A., Merino, P., et al. Immunoglobulins IgG1, IgM and IgA: a synergistic team influencing survival in sepsis. J Intern Med 276 (2014), 404–412.
13. [13] Alejandria, M.M., Lansang, M.A., Dans, L.F., Mantaring, J.B. 3rd, Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev, 9, 2013, CD001090.
14. [14] Norrby-Teglund, A., Haque, K.N., Hammarström, L., Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. J Intern Med 260 (2006), 509–516.
15. [15] Kreymann, K.G., de Heer, G., Nierhaus, A., Kluge, S., Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 35 (2007), 2677–2685.
16. [16] Berlot, G., Vassalo, M.C., Busetto, N., Bianchi, M., Zornada, F., Rosato, I., et al. Relationship between the timing of administration of IgM and IgA enriched immnoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis. J Crit Care 27 (2012), 167–171.
17. [17] Cavazzuti, I., Serafini, G., Busani, S., Rinaldi, L., Biagioni, E., Buonochristiano, M., et al. Early therapy with IgM-enriched polyclonal immunoglobulin in patients with septic shock. Intensive Care Med 40 (2014), 1888–1896.
18. [18] Bass, S.N., Bauer, S.R., Neuner, E.A., Lam, S.W., Impact of combination antimicrobial therapy on mortality risk for critically ill patients with carbapenem-resistant bacteremia. Antimicrob Agents Chemother 59 (2015), 3748–3753.
19. [19] Patel, S.J., Oliveira, A.P., Zhou, J.J., Alba, L., Furuya, E.Y., Weisenberg, S.A., et al. Risk factors and outcomes of infections caused by extremely drug-resistant gram-negative bacilli in patients hospitalized in intensive care units. Am J Infect Control 42 (2014), 626–631.